Transgenic plants are an attractive alternative to produce antibodies for the manufacturing of biologics. The main subject of this study was to assess two non-commercial transgenic tobacco plant varieties (BHmN and Habana 92) cultivated in zeolite and confined conditions for the production of a hepatitis B virus surface antigen (HBsAg)-specific plantibody (PHB-01). The plantibody molecule biochemical characterization and the assessment of the immunopurification capacity of the antigen recognized by PHB-01-immunoadsorbents were other subjects studied in this study to decide which variety would be more suitable for PHB-01 large-scale production. As results, the BHmN variety allowed obtaining 1.18 fold more biomass of leaves and up to 2 fold in the pantibody yield with similar specificity and affinity constant by the HBsAg. The assessment of the HBsAg immunopurification capacity of the PHB-01 immunoadsorbents produced by these two non-commercial transgenic plant varieties did not showed significant differences in terms of adsorption capacity (p = 0.2135), elution capacity (p = 0.1239), recovery (p = 0.2655) and purity during 13 purification cycles. In conclusion, the BHmN variety would be the most suitable variety for the production of the PHB-01.